Farzana Pashankar1, Juliet P Hale2, Ha Dang3, Mark Krailo4, William E Brady5, Carlos Rodriguez-Galindo6, James C Nicholson7, Matthew J Murray7, Deborah F Bilmire8, Sara Stoneham9, G Suren Arul10, Thomas A Olson11, Daniel Stark12, Furqan Shaikh13, James F Amatruda14,15, Allan Covens13, David M Gershenson16, A Lindsay Frazier6. 1. Yale University School of Medicine, New Haven, Connecticut. 2. Department of Paediatric Oncology, Royal Victoria Infirmary, Newcastle Upon Tyne Hospitals Trust, Newcastle Upon Tyne, United Kingdom. 3. Children's Oncology Group, Monrovia, California. 4. University of Southern California, Los Angeles, California. 5. Gynecologic Oncology Group Statistics and Data Center, Roswell Park Cancer Institute, Buffalo, New York. 6. Dana-Farber Cancer Institute and Boston Children's Hospital, Boston, Massachusetts. 7. Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom. 8. Riley Hospital for Children, Indianapolis, Indiana. 9. Children's and Young Persons Cancer Services, University College London Hospital Trusts, London, United Kingdom. 10. Birmingham Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom. 11. Aflac Cancer Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia. 12. Leeds Institute of Cancer Studies and Pathology, Leeds Institute of Oncology and St. James's University Hospital, Leeds, United Kingdom. 13. University of Toronto, Toronto, Canada. 14. University of Texas Southwestern Medical Center, Dallas, Texas. 15. Children's Medical Center, Dallas, Texas. 16. The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: There is a debate regarding the management of ovarian immature teratomas (ITs). In adult women, postoperative chemotherapy is standard except for stage I, grade 1 disease, whereas surgery alone is standard in pediatric patients. To determine the role of chemotherapy, a pooled analysis of pediatric and adult clinical trials was conducted. METHODS: Data from 7 pediatric trials and 2 adult trials were merged in the Malignant Germ Cell International Collaborative data set. Four trials included patients with newly diagnosed pure ovarian ITs and were selected (Pediatric Oncology Group/Children's Cancer Group Intergroup Study (INT 0106), Second UKCCSG Germ Cell Tumor Study (GC2), Gynecologic Oncology Group (GOG 0078 and GOG 0090). Adult and pediatric trials were analyzed separately. The primary outcome measures were event-free survival (EFS) and overall survival (OS). RESULTS: One hundred seventy-nine patients were included (98 pediatric patients and 81 adult patients). Ninety pediatric patients were treated with surgery alone, whereas all adult patients received chemotherapy. The 5-year EFS and OS were 91% and 99%, respectively, for the pediatric cohort and 87% and 93%, respectively, for the adults. There were no relapses in grade 1 patients, regardless of the stage or age. Only 1 adult patient with a grade 2 IT relapsed. Among grade 3 patients, the 5-year EFS was 0.92 (0.72-0.98) for stage I/II and 0.52 (0.22-0.75) for stage III in the pediatric cohort (P = .005) and 0.91 (0.69-0.98) for stage I/II and 0.65 (0.39-0.83) for stage III/IV in the adult cohort (P = .01). Postoperative chemotherapy did not decrease relapses in the pediatric cohort. CONCLUSIONS: The grade was the most important risk factor for relapse in ovarian ITs. Among grade 3 patients, the stage was significantly associated with relapse. Adjuvant chemotherapy did not decrease relapses in the pediatric cohort; its role in adults remains unresolved. Cancer 2016;122:230-237.
BACKGROUND: There is a debate regarding the management of ovarian immature teratomas (ITs). In adult women, postoperative chemotherapy is standard except for stage I, grade 1 disease, whereas surgery alone is standard in pediatric patients. To determine the role of chemotherapy, a pooled analysis of pediatric and adult clinical trials was conducted. METHODS: Data from 7 pediatric trials and 2 adult trials were merged in the Malignant Germ Cell International Collaborative data set. Four trials included patients with newly diagnosed pure ovarian ITs and were selected (Pediatric Oncology Group/Children's Cancer Group Intergroup Study (INT 0106), Second UKCCSG Germ Cell Tumor Study (GC2), Gynecologic Oncology Group (GOG 0078 and GOG 0090). Adult and pediatric trials were analyzed separately. The primary outcome measures were event-free survival (EFS) and overall survival (OS). RESULTS: One hundred seventy-nine patients were included (98 pediatric patients and 81 adult patients). Ninety pediatric patients were treated with surgery alone, whereas all adult patients received chemotherapy. The 5-year EFS and OS were 91% and 99%, respectively, for the pediatric cohort and 87% and 93%, respectively, for the adults. There were no relapses in grade 1 patients, regardless of the stage or age. Only 1 adult patient with a grade 2 IT relapsed. Among grade 3 patients, the 5-year EFS was 0.92 (0.72-0.98) for stage I/II and 0.52 (0.22-0.75) for stage III in the pediatric cohort (P = .005) and 0.91 (0.69-0.98) for stage I/II and 0.65 (0.39-0.83) for stage III/IV in the adult cohort (P = .01). Postoperative chemotherapy did not decrease relapses in the pediatric cohort. CONCLUSIONS: The grade was the most important risk factor for relapse in ovarian ITs. Among grade 3 patients, the stage was significantly associated with relapse. Adjuvant chemotherapy did not decrease relapses in the pediatric cohort; its role in adults remains unresolved. Cancer 2016;122:230-237.
Authors: U Göbel; G Calaminus; J Engert; P Kaatsch; H Gadner; J P Bökkerink; R J Hass; K Waag; M E Blohm; S Dippert; C Teske; D Harms Journal: Med Pediatr Oncol Date: 1998-07
Authors: U Göbel; G Calaminus; M Blohm; D Booss; F Felberbauer; U Hofmann; A M Holschneider; U Willnow; D Harms Journal: Klin Padiatr Date: 1997 Jul-Aug Impact factor: 1.349
Authors: Danielle Vicus; Mario E Beiner; Blaise Clarke; Shany Klachook; Lisa W Le; Stephane Laframboise; Helen Mackay Journal: Gynecol Oncol Date: 2011-07-20 Impact factor: 5.482
Authors: S A Heifetz; B Cushing; R Giller; J J Shuster; C J Stolar; C D Vinocur; E P Hawkins Journal: Am J Surg Pathol Date: 1998-09 Impact factor: 6.394
Authors: N M Marina; B Cushing; R Giller; L Cohen; S J Lauer; A Ablin; R Weetman; J Cullen; P Rogers; C Vinocur; C Stolar; F Rescorla; E Hawkins; S Heifetz; P V Rao; M Krailo; R P Castleberry Journal: J Clin Oncol Date: 1999-07 Impact factor: 44.544
Authors: Jillian R Mann; Elizabeth S Gray; Claire Thornton; Faro Raafat; Kathleen Robinson; Gary S Collins; Peter Gornall; Simon N Huddart; Juliet P Hale; Anthony Oakhill Journal: J Clin Oncol Date: 2008-06-09 Impact factor: 44.544
Authors: A F Leary; M Quinn; K Fujiwara; R L Coleman; E Kohn; T Sugiyama; R Glasspool; I Ray-Coquard; N Colombo; M Bacon; A Zeimet; A Westermann; E Gomez-Garcia; D Provencher; S Welch; W Small; D Millan; A Okamoto; G Stuart; K Ochiai Journal: Ann Oncol Date: 2017-04-01 Impact factor: 32.976
Authors: C Newton; K Murali; A Ahmad; H Hockings; R Graham; V Liberale; S-J Sarker; J Ledermann; D M Berney; J Shamash; S Banerjee; S Stoneham; M Lockley Journal: Eur J Cancer Date: 2019-04-04 Impact factor: 9.162
Authors: Asaf Maoz; Koji Matsuo; Marcia A Ciccone; Shinya Matsuzaki; Maximilian Klar; Lynda D Roman; Anil K Sood; David M Gershenson Journal: Cancers (Basel) Date: 2020-05-29 Impact factor: 6.639
Authors: Gabriele Calaminus; Dominik T Schneider; Dietrich von Schweinitz; Heribert Jürgens; Nacera Infed; Stefan Schönberger; Thomas A Olson; Peter Albers; Christian Vokuhl; Raimund Stein; Leendert Looijenga; Jalid Sehouli; Martin Metzelder; Alexander Claviez; Michael Dworzak; Angelika Eggert; Birgit Fröhlich; Nicolas U Gerber; Christian P Kratz; Jörg Faber; Thomas Klingebiel; Dieter Harms; Ulrich Göbel Journal: Cancers (Basel) Date: 2020-03-06 Impact factor: 6.639